当前位置:首页 - 行情中心 - 奥翔药业(603229) - 财务分析 - 现金流量表

奥翔药业

(603229)

  

流通市值:61.68亿  总市值:61.68亿
流通股本:5.93亿   总股本:5.93亿

现金流量表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金569,754,749.01427,014,012.02208,507,860.64728,521,421.31
收到的税费返还37,382,108.5531,617,886.3710,439,152.5229,860,671.28
收到其他与经营活动有关的现金101,763,947.4369,071,577.5669,019,109.52131,260,004.61
经营活动现金流入的平衡项目0000
经营活动现金流入小计708,900,804.99527,703,475.95287,966,122.68889,642,097.2
购买商品、接受劳务支付的现金411,046,333.04275,344,119.88161,592,423.95456,417,703.55
支付给职工以及为职工支付的现金143,077,558.38100,948,174.2359,126,401154,076,490.18
支付的各项税费29,502,294.2420,592,380.971,508,832.4136,214,710.6
支付其他与经营活动有关的现金114,988,152.3290,355,474.0220,782,551.55122,366,159.19
经营活动现金流出的平衡项目0000
经营活动现金流出小计698,614,337.98487,240,149.1243,010,208.91769,075,063.52
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额10,286,467.0140,463,326.8544,955,913.77120,567,033.68
二、投资活动产生的现金流量:
处置固定资产、无形资产和其他长期资产收回的现金净额---186,789
收到的其他与投资活动有关的现金6,114,746.061,277,395.061,259,895.06619,485,191.07
投资活动现金流入的平衡项目0000
投资活动现金流入小计6,114,746.061,277,395.061,259,895.06619,671,980.07
购建固定资产、无形资产和其他长期资产支付的现金98,001,271.8449,795,389.7264,566,155.55271,913,863.21
投资支付的现金18,000,00017,500,00017,500,00017,500,000
支付其他与投资活动有关的现金315,281.01315,281.01315,281.01508,105,092.4
投资活动现金流出的平衡项目0000
投资活动现金流出小计116,316,552.8567,610,670.7382,381,436.56797,518,955.61
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-110,201,806.79-66,333,275.67-81,121,541.5-177,846,975.54
三、筹资活动产生的现金流量:
吸收投资收到的现金473,933,781.92473,933,781.92473,933,781.92-
取得借款收到的现金200,000,000200,000,000100,000,000235,050,000
收到其他与筹资活动有关的现金11,167,901.2411,167,901.24-11,858,240.33
筹资活动现金流入平衡项目0000
筹资活动现金流入小计685,101,683.16685,101,683.16573,933,781.92246,908,240.33
偿还债务支付的现金131,230,000131,230,0009,950,000103,150,000
分配股利、利润或偿付利息支付的现金55,306,345.335,355,378.512,699,663.4437,672,915.63
支付其他与筹资活动有关的现金22,483,512.8325,897,749.7217,992,885.9311,167,901.24
筹资活动现金流出平衡项目0000
筹资活动现金流出小计209,019,858.16162,483,128.2330,642,549.37151,990,816.87
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额476,081,825522,618,554.93543,291,232.5594,917,423.46
四、汇率变动对现金及现金等价物的影响11,886,069.5616,255,778.37-5,241,046.1537,180,756.74
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额388,052,554.78513,004,384.48501,884,558.6774,818,238.34
加:期初现金及现金等价物余额563,746,689.41563,746,689.41563,746,689.41488,928,451.07
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额951,799,244.191,076,751,073.891,065,631,248.08563,746,689.41
补充资料:
净利润-160,196,748.33-235,375,827.46
资产减值准备-2,378,743.32-4,949,851.07
固定资产和投资性房地产折旧-17,804,117.26-30,430,293.23
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-17,804,117.26-30,430,293.23
无形资产摊销-1,893,161.88-4,047,415.63
固定资产报废损失---1,584,815.82
公允价值变动损失--3,042,877.03--4,946,902.51
财务费用--16,364,813.5--34,533,544.75
投资损失--962,114.05--1,380,098.67
递延所得税--1,309,247.32-10,117,618.37
其中:递延所得税资产减少--1,813,468.87--2,396,441.54
递延所得税负债增加-504,221.55-12,514,059.91
存货的减少--29,882,470.7--153,136,819.57
经营性应收项目的减少--136,023,998.87--69,410,444.56
经营性应付项目的增加-40,524,514.23-97,469,022.16
现金的期末余额-1,076,751,073.89-563,746,689.41
减:现金的期初余额-563,746,689.41-488,928,451.07
公告日期2023-10-282023-08-302023-04-282023-04-28
审计意见(境内)标准无保留意见
TOP↑